← Eichor
Condition: Lymphoma Primary Effusion Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lymphoma Primary Effusion

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Natural History of KSHV-Associated Multicentric Castleman s Disease
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT04968288
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cance
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT00006518
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/Phase 2 · 2 location(s) · Estrella Biopharma, Inc. · NCT06343311
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Diseas
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05907759
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 · 36 location(s) · Schrödinger, Inc. · NCT05544019
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.